503A vs 503B Compounding: Two Pathways, and Where GLP-1s Stand
Understanding 503A vs 503B compounding is central to following the current wave of peptide regulatory news. These are two separate legal pathways in United States law that govern how a pharmacy or facility may prepare, or “compound,” a medication that is not a standard mass-manufactured product. They are defined under different sections of the Federal Food, Drug, and Cosmetic Act, and they carry different rules, oversight, and lists of permitted bulk substances.
Section 503A: traditional pharmacy compounding
Section 503A describes traditional compounding, in which a licensed pharmacist or physician prepares a medication for an identified patient, typically in response to a prescription. Compounders operating under 503A are generally not required to register with the FDA as drug manufacturers or to follow the full current good manufacturing practice (CGMP) requirements that apply to commercial drug production. When a 503A pharmacy uses a bulk drug substance, that substance must appear on an FDA-recognized list, be the subject of an applicable monograph, or be a component of an FDA-approved drug.
Section 503B: outsourcing facilities
Section 503B was added to the law in 2013 and created a category known as outsourcing facilities. These facilities may compound larger batches, including preparations not tied to an individual prescription, but in exchange they register with the FDA, are subject to CGMP requirements, and face additional inspection and reporting obligations. A 503B facility may compound from a bulk drug substance only if that substance is on the separate 503B bulks list, which the FDA develops based on a finding of clinical need.
Where peptides and GLP-1s currently stand
Recent activity has moved along both tracks at once, which is a common source of confusion. On the 503A side, the FDA’s Pharmacy Compounding Advisory Committee reviewed several research peptides for possible addition to the 503A bulks list. Separately, on the 503B side, the FDA published a proposal to exclude the GLP-1 substances semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it had not identified a clinical need for outsourcing facilities to compound them from bulk. According to the Federal Register, the public comment period on that proposal was extended and has since closed; as of publication, the agency has not issued a final determination.
The key point for readers following these developments: a published proposal is not the same as a final rule, and a committee recommendation is advisory rather than binding. Both pathways can change independently, and each has its own list, its own process, and its own timeline.
503A vs 503B at a glance
- 503A — patient-specific prescriptions; licensed pharmacy; not registered as a drug manufacturer; bulk substances limited to the 503A list or FDA-approved drugs.
- 503B — outsourcing facilities; may compound without patient-specific prescriptions; registers with FDA and follows CGMP; bulk substances limited to the 503B “clinical need” list.
For more on the July committee vote, see our coverage of the FDA peptide compounding vote. To understand the quality documents referenced throughout compounding discussions, see how to read a Certificate of Analysis, and browse the latest updates on our news page.
